Additionally, Pfizer has yet to announce the Fabry deal, which is anticipated to be a key driver for stock movement. An announcement is expected by the end of January, potentially influencing investor sentiment.

If Pfizer presents new and improved data at ASH (different from what was shared at previous conferences), the stock price could see an upward move.
If the data presented aligns with earlier results, the stock may experience a short-term dip.

While a specific FDA submission date is pending, further analysis of the data is ongoing, with results set to be presented at ASH and other upcoming medical conferences.

Looking ahead to next week, two possible outcomes could impact the stock:

• Zinsner highlighted that the Chips Act grant is an “ironclad agreement.”
• He also noted that Intel’s next CEO will prioritize manufacturing and product expertise. #intel #mchp #asml

CEO Arkady Volozh is the real deal. $NVDA's investment was not out of the blue, they have known the company for a decade and were waiting for complete divesture. So much optionality in so many